POSA49 Projecting the Long-Term Benefits of Venetoclax Combination Therapies for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy: An Assessment of Net Health Benefit
| Autor: | Schuh, AC, Pratz, K, Lachaine, J, Suh, HS, Li, X, Chai, X, Xie, J, Gu, C, Bui, CN |
|---|---|
| Zdroj: | In Value in Health January 2022 25(1) Supplement:S42-S42 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect